BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4635 related articles for article (PubMed ID: 25419744)

  • 1. Detailed protocol for administration of intralesional IL-2 for the treatment of Stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines.
    Patel F; Wilken R; Burrall B; Martinez S; Wells V; King B; Maverakis E
    Dermatol Online J; 2014 Nov; 20(11):. PubMed ID: 25419744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series.
    Shi VY; Tran K; Patel F; Leventhal J; Konia T; Fung MA; Wilken R; Garcia MS; Fitzmaurice SD; Joo J; Monjazeb AM; Burrall BA; King B; Martinez S; Christensen SD; Maverakis E
    J Am Acad Dermatol; 2015 Oct; 73(4):645-54. PubMed ID: 26259990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2].
    Dehesa LA; Vilar-Alejo J; Valerón-Almazán P; Carretero G
    Actas Dermosifiliogr; 2009 Sep; 100(7):571-85. PubMed ID: 19715642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternatives for the treatment of local advanced disease: electrochemotherapy, limb perfusion, limb infusion, intralesional IL2. What is the role?
    Testori A; Intelisano A; Verrecchia F; Menicanti C; Tosti G; Grassi E; Pari C; Pennacchioli E
    Dermatol Ther; 2012; 25(5):443-51. PubMed ID: 23046023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic melanoma - a review of current and future treatment options.
    Maverakis E; Cornelius LA; Bowen GM; Phan T; Patel FB; Fitzmaurice S; He Y; Burrall B; Duong C; Kloxin AM; Sultani H; Wilken R; Martinez SR; Patel F
    Acta Derm Venereol; 2015 May; 95(5):516-24. PubMed ID: 25520039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-lesional interleukin-2 for the treatment of in-transit melanoma.
    Boyd KU; Wehrli BM; Temple CL
    J Surg Oncol; 2011 Dec; 104(7):711-7. PubMed ID: 21744347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.
    Radny P; Caroli UM; Bauer J; Paul T; Schlegel C; Eigentler TK; Weide B; Schwarz M; Garbe C
    Br J Cancer; 2003 Nov; 89(9):1620-6. PubMed ID: 14583759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
    Takkenberg RB; Vrouenraets BC; van Geel AN; Nieweg OE; Noorda EM; Eggermont AM; Kroon BB
    J Surg Oncol; 2005 Aug; 91(2):107-11. PubMed ID: 16028280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intralesional therapy for in-transit and satellite metastases in melanoma.
    Feeney KJ; Mastrangelo MJ
    Surg Oncol Clin N Am; 2015 Apr; 24(2):299-308. PubMed ID: 25769713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream.
    Garcia MS; Ono Y; Martinez SR; Chen SL; Goodarzi H; Phan T; Wehrli LN; Miyamura Y; Fung MA; Maverakis E
    Melanoma Res; 2011 Jun; 21(3):235-43. PubMed ID: 21464773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up.
    Weide B; Eigentler TK; Pflugfelder A; Leiter U; Meier F; Bauer J; Schmidt D; Radny P; Pföhler C; Garbe C
    Cancer Immunol Immunother; 2011 Apr; 60(4):487-93. PubMed ID: 21174093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.
    Green DS; Bodman-Smith MD; Dalgleish AG; Fischer MD
    Br J Dermatol; 2007 Feb; 156(2):337-45. PubMed ID: 17223875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.
    Weide B; Eigentler TK; Pflugfelder A; Zelba H; Martens A; Pawelec G; Giovannoni L; Ruffini PA; Elia G; Neri D; Gutzmer R; Becker JC; Garbe C
    Cancer Immunol Res; 2014 Jul; 2(7):668-78. PubMed ID: 24906352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Imiquimod, pegylated interferon-alpha-2b and interleukin-2 in the treatment of cutaneous melanoma metastases].
    Loquai C; Nashan D; Metze D; Beiteke U; Rüping KW; Luger TA; Grabbe S
    Hautarzt; 2004 Feb; 55(2):176-81. PubMed ID: 14968329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in 2 patients with malignant melanoma].
    Pföhler C; Steinhäuser S; Wagner A; Ugurel S; Tilgen W
    Hautarzt; 2004 Feb; 55(2):171-5. PubMed ID: 14968328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma.
    Weide B; Derhovanessian E; Pflugfelder A; Eigentler TK; Radny P; Zelba H; Pföhler C; Pawelec G; Garbe C
    Cancer; 2010 Sep; 116(17):4139-46. PubMed ID: 20564107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous melanoma: available therapy for metastatic disease.
    Tarhini AA; Agarwala SS
    Dermatol Ther; 2006; 19(1):19-25. PubMed ID: 16405566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of metastasized malignant melanoma].
    Kamanabrou D
    Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The intralesional interleukin-2 is an adequate palliative treatment in cutaneous metastases of melanoma.
    Menis D; Monsalvez-Honrubia V; Maroñas-Jiménez L; Morales-Raya C; Ortiz-Romero PL
    G Ital Dermatol Venereol; 2017 Aug; 152(4):400-401. PubMed ID: 28621122
    [No Abstract]   [Full Text] [Related]  

  • 20. Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients.
    Ridolfi L; Ridolfi R; Ascari-Raccagni A; Fabbri M; Casadei S; Gatti A; Trevisan G; Righini MG
    J Eur Acad Dermatol Venereol; 2001 May; 15(3):218-23. PubMed ID: 11683284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 232.